1. A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial)
- Author
-
Yoshihiro Mise, Yukihiro Nomura, Eiji Shinozaki, Seiichi Yamagata, Masaru Oba, Shinichi Miyagawa, Junji Yamamoto, Hiroaki Nozawa, Yojiro Hashiguchi, Nobuyoshi Aoyanagi, Shuntaro Yoshida, Norihiro Kokudo, Hirohiko Sakamoto, Kiyoshi Hasegawa, Hironori Kaneko, Masayuki Shibasaki, Akio Saiura, Tadatoshi Takayama, and Hiroto Koyama
- Subjects
Surgical resection ,medicine.medical_specialty ,Organoplatinum Compounds ,Leucovorin ,Cetuximab ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,Medicine ,Humans ,business.industry ,Liver Neoplasms ,Induction chemotherapy ,Cytoreduction Surgical Procedures ,Induction Chemotherapy ,Combined Modality Therapy ,Confidence interval ,Surgery ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,KRAS ,Fluorouracil ,business ,Colorectal Neoplasms ,medicine.drug - Abstract
The effect of cetuximab plus mFOLFOX on downsizing of the tumors for curative resection has yet to be assessed for patients with advanced colorectal liver metastases (CRLMs). This study aimed to assess the oncologic benefit of cetuximab plus mFOLFOX for wild-type KRAS patients with advanced CRLMs. In this multicenter phase 2 trial, patients with technically unresectable tumor and/or five or more CRLMs harboring wild-type KRAS were treated with mFOLFOX plus cetuximab. The patients were assessed for resectability after 4 treatments, and then every 2 months up to 12 treatments. Patients with resectable disease were offered surgery after a waiting period of 1 month. The primary end point of the study was the R0 resection rate. The secondary end points were safety, progression-free survival (PFS), and overall survival (OS). The study is registered with the University Hospital Medical Information Network-Clinical Trials Registry Clinical Trials Registry (no. C000007923). Between 2012 and 2015, 50 patients from 13 centers were enrolled in this trial. Two patients were excluded because they had not received induction therapy. The 48 patients had a complete response rate of 0% and a partial response rate of 64.6%. For 26 R0 resections (54.2%) and 5 R1 resections (10.4%), no mortality occurred. During a median follow-up period of 31 months, the median OS for all the patients was calculated to be 41 months (95% confidence interval, 28–not reached). The 3-year OS rate was 59%. For patients with advanced CRLMs harboring wild-type KRAS, cetuximab administered in combination with mFOLFOX yields high response rates, leading to significantly high R0 resection rates and favorable prognoses.
- Published
- 2020